Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2174-2184

  Chimalakonda, Krishna C ^a   Seely, Kathryn A ^b   Bratton, Stacie M ^a   Brents, Lisa K ^a   Moran, Cindy L ^c   Endres, Gregory W ^d   James, Laura P ^a   Hollenberg, Paul F ^e   Prather, Paul L ^a   Radominska Pandya, Anna ^a   Moran, Jeffery H ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS DEPARTMENT OF HEALTH   (United States)

^c Arkansas State Crime Laboratory   (United States)

^d Cayman Chemical Company   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 METHANESULFONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; [1 (5 FLUOROPENTYL) 1H INDOL 3 YL] 1 NAPHTHALENYL METHANONE; AM 2201; BETA GLUCURONIDASE; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID DERIVATIVE; CYTOCHROME P450; O 2050; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; BINDING AFFINITY; BIOTRANSFORMATION; CARBOXYLATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINALYSIS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CANNABINOIDS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; INDOLES; KINETICS; LIGANDS; LIVER; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; NAPHTHALENES; OXIDATION-REDUCTION; PROTEIN BINDING; PYRANS; RECEPTOR, CANNABINOID, CB1; STREET DRUGS; TETRAHYDROCANNABINOL;

EID: 84867684839     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047530     Document Type: Article

References (56)

1. Adams IB and Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585-1614. (Pubitemid 26393422)
2. Atwood BK, Huffman J, Straiker A, and Mackie K (2010) JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585-593.
3. Banken JA (2004) Drug abuse trends among youth in the United States. Ann NY Acad Sci 1025:465-471.
4. Benford DM and Caplan JP (2011) Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 52:295.
5. 9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096-1103.
6. 1-tetrahydrocannabinol. Drug Metab Dispos 20:241-246.
7. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, and Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952-961.
8. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, and Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917.
9. Budney AJ and Hughes JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry 19:233-238. (Pubitemid 44309479)
10. Camp NE (2011) Synthetic cannabinoids. J Emerg Nurs 37:292-293.
11. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, and Radominska-Pandya A (2011a) Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP- glucuronosyltransferases. Drug Metab Dispos 39:1967-1976.
13. Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, et al. (2011b) Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem 83:6381-6388.
14. Compton DR, Gold LH, Ward SJ, Balster RL, and Martin BR (1992a) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126. (Pubitemid 23157189)
15. Compton DR, Johnson MR, Melvin LS, and Martin BR (1992b) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
16. Dresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R, and Auwärter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186-1194.
17. European Monitoring Centre for Drugs and Drug Addiction (2009) Understanding the 'Spice' phenomenon, in EMCDDA 2009, pp 1-25, Office for Official Publications of the European Communities, Lisbon, Portugal.
18. Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117:152-157.
19. Hu X, Primack BA, Barnett TE, and Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16.
20. Huffman JW and Padgett LW (2005) Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 12:1395-1411. (Pubitemid 40872583)
21. Hutter M, Broecker S, Kneisel S, and Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J Mass Spectrom 47:54-65.
22. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
23. Jones RT (2002) Cardiovascular system effects of marijuana. J Clin Pharmacol 42:58S-63S.
24. Kacinko SL, Xu A, Homan JW, McMullin MM, Warrington DM, and Logan BK (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 35:386-393.
25. 9-tetrahydrocannabinol in human tissues by GC-MS. J Anal Toxicol 19:87-90.
26. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, and Moran JH (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 49:760-764.
27. Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20 (Suppl 1):10-14.
28. Meyer RP, Gehlhaus M, Knoth R, and Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8:297-306. (Pubitemid 46780059)
29. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, et al. (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228-4236.
30. Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, and Maler JM (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118:309-310.
31. Ortiz de Montellano PR (1995) Human Cytochrome P450 enzymes, in Cytochrome P-450: Structure, Mechanism, and Biochemistry, 2nd ed., (Ortiz De Montellano PR ed), pp 473-535, Plenum Publishing Corp, New York.
32. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
33. Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, and Teran GA (2012) Spicy seizure. Am J Med Sci 344:67-68.
34. Prather PL, Martin NA, Breivogel CS, and Childers SR (2000) Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein α-subunits with different potencies. Mol Pharmacol 57:1000-1010. (Pubitemid 30253385)
35. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178. (Pubitemid 38299716)
36. Randall MD, Kendall DA, and O'Sullivan S (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142:20-26. (Pubitemid 38698188)
37. Rowland-Yeo K, Rostami-Hodjegan A, and Tucker GT (2003) Abundance of cytochrome P450 in human liver: a meta-analysis, in Proceedings of the British Pharmacology Society Winter Meeting; 2003 Dec 16-18; London, UK. British Pharmacology Society, London, UK.
38. Schneir AB, Cullen J, and Ly BT (2011) "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 40:296-299.
39. Seely KA, Lapoint J, Moran JH, and Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry http://dx.doi.org/10.1016/j.pnpbp.2012.04.017.
40. Seely KA, Prather PL, James LP, and Moran JH (2011) Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 11:36-51.
41. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, and Prather PL (2005) The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther 314:868-875. (Pubitemid 41043873)
42. Simmons J, Cookman L, Kang C, and Skinner C (2011a) Three cases of "spice" exposure. Clin Toxicol (Phila) 49:431-433.
43. Simmons JR, Skinner CG, Williams J, Kang CS, Schwartz MD, and Wills BK (2011b) Intoxication from smoking "spice." Ann Emerg Med 57:187-188.
44. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538-545.
45. Sobolevsky T, Prasolov I, and Rodchenkov G (2010) Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 200:141-147.
46. Thakur GA, Nikas SP, and Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631-640. (Pubitemid 40933034)
47. Vearrier D and Osterhoudt KC (2010) A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 26:462-465.
48. 9- tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352-363.
49. Ward SJ, Baizman E, Bell M, Childers S, D'Ambra T, Eissenstat M, Estep K, Haycock D, Howlett A, and Luttinger D (1990) Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? NIDA Res Monogr 105:425-426.
50. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, and Yoshimura H (1995) Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138-1141.
51. Watanabe K, Yamaori S, Funahashi T, Kimura T, and Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415-1419. (Pubitemid 46367067)
52. Wells DL and Ott CA (2011) The "new" marijuana. Ann Pharmacother 45:414-417.
53. Wintermeyer A, Möller I, Thevis M, Jübner M, Beike J, Rothschild MA, and Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141-2153.
54. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, and Kleinschmidt K (2011) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 30:1320.e5-1320.e7.
55. Zhang Q, Ma P, Iszard M, Cole RB, Wang W, and Wang G (2002) In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos 30:1077-1086.
56. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, and Schulz K (2009) Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch Arztebl Int 106:464-467.